CN Patent

CN115209882A — 用大麻二酚与依维莫司治疗结节性硬化复合症的方法

Assigned to Jiwei Research Co ltd · Expires 2022-10-18 · 4y expired

What this patent protects

本发明涉及大麻二酚(CBD)制备物用于在治疗与结节性硬化复合症(TSC)相关的癫痫发作中使用的用途。特别地，本发明包括将依维莫司与减少剂量的大麻二酚(CBD)联合施用。在可选的实施方案中，本发明涉及目前用CBD治疗的未使用依维莫司的患者中与结节性硬化复合症相关的癫痫发作的治疗。优选地，依维莫司的剂量减少至少10％。

USPTO Abstract

本发明涉及大麻二酚(CBD)制备物用于在治疗与结节性硬化复合症(TSC)相关的癫痫发作中使用的用途。特别地，本发明包括将依维莫司与减少剂量的大麻二酚(CBD)联合施用。在可选的实施方案中，本发明涉及目前用CBD治疗的未使用依维莫司的患者中与结节性硬化复合症相关的癫痫发作的治疗。优选地，依维莫司的剂量减少至少10％。

Drugs covered by this patent

Patent Metadata

Patent number
CN115209882A
Jurisdiction
CN
Classification
—
Expires
2022-10-18
Drug substance claim
No
Drug product claim
No
Assignee
Jiwei Research Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.